Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

AIMS: The metabolic pathways leading to the formation of prasugrel and clopidogrel active metabolites differ. We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. METHODS AND RESULTS: Ninety-eight patients with cor...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Varenhorst, Christoph, James, Stefan, Erlinge, David, Brandt, John T., Braun, Oscar Ö., Man, Michael, Siegbahn, Agneta, Walker, Joseph, Wallentin, Lars, Winters, Kenneth J., Close, Sandra L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2009
Konular:
Clinical Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2709885/
https://ncbi.nlm.nih.gov/pubmed/19429918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehp157
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller